August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Corporate News Release

Bioniche Further Pays Down Debt with Laurus Master Funds

12/01/07

- an additional $1 million USD of debt removed from balance sheet -

BELLEVILLE, ON, January 12, 2007 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Company will repay an additional $1 million USD of its debt with Laurus Master Funds.

The Company will repay $500,000 USD on the secured convertible term note and $500,000 USD on the secured revolving note in shares. For the convertible term note repayment, the shares will be priced at $0.88 Cdn. For the secured revolving note repayment, the shares will be priced at the ten day market average (VWAP) less 15%. This will equate to 1,077,840 shares. There is no penalty attached to this repayment.

Following this transaction, Bioniche will have a net convertible term debt of approximately $0.56 million USD and a maximum borrowing limit under the revolving note of up to $3.5 million USD.

“We continue to improve our balance sheet,” said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. “This puts us in a better position to execute our Phase III development program for Urocidin, while completing a partnership deal and/or a strategic financing arrangement to support our business model.”

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Food Safety
Human Health